References of "Paul, I"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEtude pilote pour le developpement d'un registre de l'infarctus du myocarde en region liegeoise (Belgique)
Paul, I.; Bilge, A.; Bolly, F. et al

in Revue d'Epidémiologie et de Santé Publique (2001), 49(5), 423-9

BACKGROUND: In 1998, a permanent registry of myocardial infarction was developed in the Liege area (Belgium) to provide updated, exhaustive and validated data on the morbidity and mortality from ... [more ▼]

BACKGROUND: In 1998, a permanent registry of myocardial infarction was developed in the Liege area (Belgium) to provide updated, exhaustive and validated data on the morbidity and mortality from cardiovascular causes, to define the patients' profile, to identify myocardial infarction therapeutic strategies and to complete and make comparisons with data collected in other parts of the country through methodologically identical registers. METHODS: All acute coronary events lethal or non lethal among individuals from both genders aged from 25 to 69 years and living in the area were registered according to the methodology developed for the MONICA project (Multinational Monitoring of Trends and Determinants in Cardiovascular Diseases) of WHO. The three main selected data sources were: death certificates, general practitioners and cardiologists, hospitals. The events were categorised according to symptoms, cardiac enzymes, electrocardiogram, history of chronic ischaemic heart disease and necropsy findings. RESULTS: The coronary-event rates were 283/100,000 in men and 102/100,000 in women. The case fatality rate, 28 days after the onset of the symptoms, was 30.6% for men and 36.2% for women, and 77.5% of deaths occurred in the first 24 hours after the onset of the symptoms. CONCLUSION: The development of a myocardial infarction register at a regional level requires the involvement of all health professionals dealing with that pathology. Such register has valuable public health interests, providing exhaustive and validated data on the pathology and its evolution as well as useful information for improving therapeutic strategies and developing adapted preventive measures. [less ▲]

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailComment positionner l'acéclofénac au sein de l'arsenal thérapeutique des pathologies ostéo-articulaires chroniques ?
Reginster, Jean-Yves ULg; Paul, I.; Henrotin, Yves ULg

in Revue Médicale de Liège (2001), 56(7), 484-8

The aim of this article is to critically review the potential role of aceclofenac in the treatment of inflammatory pain and chronic osteoarticular disorder, based on its activity on the mediators of ... [more ▼]

The aim of this article is to critically review the potential role of aceclofenac in the treatment of inflammatory pain and chronic osteoarticular disorder, based on its activity on the mediators of inflammation, its effect on cartilage remodeling and on the results of clinical studies comparing aceclofenac with other NSAIDs in these disorders. Aceclofenac has an outstanding anti-inflammatory profile, involving besides a classical inhibition of prostaglandins E2, a decrease in the expression of several cytokines including interleukin 1 and tumor necrosis factor alpha. It also inhibits activated oxygen species production and influences cells adhesion. Aceclofenac and its main metabolite, 4-hydroxyaceclofenac, has positive effects on cartilage anabolism combined with modulating effect of matrix catabolism. Clinically, aceclofenac has been consistently shown to have a similar efficacy than that of widely marketed NSAIDs and a tolerance profile at least as good, if not better than the profile observed for other NSAIDs in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. As of today, no head to head comparison between aceclofenac and coxibs have been performed, nor for efficacy neither for tolerance. The specific profile of aceclofenac makes this NSAID an interesting candidate for long-term treatment of chronic rheumatic disorders as well as for treatment of acute inflammatory episodes. [less ▲]

Detailed reference viewed: 40 (3 ULg)
See detailBisphosphonates
Reginster, Jean-Yves ULg; Paul, I.; Fraikin, G. et al

in The management of the menopause : the Millenium Review (2000)

Detailed reference viewed: 7 (3 ULg)
Peer Reviewed
See detailDepressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women.
Reginster, Jean-Yves ULg; Deroisy, Rita ULg; Paul, I. et al

in Maturitas (1999), 33(2), 133-7

Major depression has been repeatedly but not consistently reported to be associated with low bone mineral density (BMD) and to an increased risk for fracture in women. We have investigated, in healthy ... [more ▼]

Major depression has been repeatedly but not consistently reported to be associated with low bone mineral density (BMD) and to an increased risk for fracture in women. We have investigated, in healthy postmenopausal women, whether depressive symptomatology, assessed by the General Health Questionnaire (GHQ), was associated to a significant decrease in BMD, hence supporting the hypothesis of an independent pathogenetic link between the two disorders. We investigated 121 postmenopausal women, aged 48-77 years, spontaneously attending a screening visit for osteoporosis in an outpatient facility. BMD of the spine and the non-dominant hip (total and neck areas) were measured by Dual Energy X-Ray absorptiometry. All subjects completed to the 'General Health Questionnaire' translated and validated in French. No significant correlations were observed between the GHQ score and BMD of the spine (P = 0.54), the total hip area (P = 0.65), or the femoral neck area (P = 0.65). No differences in terms of spinal or femoral BMD were observed between women with GHQ score < 5 or > or = 5. When comparing values of BMD between women within the upper and the lower quartiles for GHQ score, no difference was observed for spine (P = 0.69), total hip (P = 0.80), or femoral neck (P = 0.93). Similarly, GHQ scores were not significantly different when comparing women in the upper and lower quartiles of BMD distribution at the spine or the hip. In conclusion, notwithstanding the clinical pattern of postmenopausal osteoporosis can lead to depression and, on the other hand, hormonal and behavioral disturbances reported in depression might be enhancing factors for accelerated bone loss, our present results do not support the hypothesis that otherwise healthy postmenopausal women with increased depressive complaints are also more prone to exhibit osteoporotic fractures. [less ▲]

Detailed reference viewed: 17 (4 ULg)
See detailEstablished postmenopausal osteoporosis – Assessment of treatment options
Reginster, Jean-Yves ULg; Halkin, V.; Fraikin, G. et al

in Menopause Review (1999), 1(IV), 39-55

Detailed reference viewed: 5 (1 ULg)
Peer Reviewed
See detailCurrent Status of fluoride salts to treat postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Paul, I.; Gosset, Christiane ULg

in Current Opinion in Orthopaedics (1998), 9(V), 7-10

Fluoride has been used over the past 25 years as a potential treatment of established osteoporosis. Notwithstanding a consensus over its ability to stimulate bone formation, discrepant results were ... [more ▼]

Fluoride has been used over the past 25 years as a potential treatment of established osteoporosis. Notwithstanding a consensus over its ability to stimulate bone formation, discrepant results were published relating to its antifracture efficacy. Differences in the published results are likely to be linked to therapeutic regimens, fluoride formulation, and the nature of the treated populations. A critical review of the published data evaluating the antifracture efficacy of fluoride leads to the conclusion that this substance should be mainly used in postmenopausal women with low bone mineral density without prevalent fracture, that low-dose fluoride for a prolonged period should be preferred to high doses for short-term treatment, and that gastroresistant preparations are likely to be better tolerated than fluoride. [less ▲]

Detailed reference viewed: 8 (2 ULg)
Peer Reviewed
See detailVieillissement de la population: données démographiques pour la région Liégeoise
Paul, I.; Gosset, Christiane ULg

in Revue Médicale de Liège (1997), 52(4), 190-2

Detailed reference viewed: 20 (2 ULg)